Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Moderate Buy" from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $37.56.

VRDN has been the subject of several analyst reports. Royal Bank Of Canada reduced their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and issued a $36.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. The Goldman Sachs Group lowered their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, JMP Securities lowered their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded up $0.09 during mid-day trading on Monday, reaching $17.13. The stock had a trading volume of 556,531 shares, compared to its average volume of 1,153,083. The stock has a market capitalization of $1.40 billion, a P/E ratio of -4.45 and a beta of 0.39. The firm has a 50 day moving average price of $14.24 and a two-hundred day moving average price of $15.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 19.49 and a current ratio of 19.49. Viridian Therapeutics has a one year low of $9.90 and a one year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. The business's revenue was up .0% on a year-over-year basis. As a group, analysts expect that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Several large investors have recently made changes to their positions in the business. Amalgamated Bank lifted its stake in shares of Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after buying an additional 840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock valued at $669,000 after buying an additional 876 shares during the last quarter. SG Americas Securities LLC increased its holdings in Viridian Therapeutics by 2.9% in the 1st quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock worth $431,000 after buying an additional 887 shares in the last quarter. Voya Investment Management LLC increased its holdings in Viridian Therapeutics by 5.1% in the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after buying an additional 1,038 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its position in Viridian Therapeutics by 3.0% in the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after buying an additional 1,106 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.